Waverley Pharma Inc. WAVE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -84.55% | 13.13% | 48.24% | 83.75% | 82.41% |
| Total Depreciation and Amortization | 26.54% | 85.09% | 244.51% | -3.25% | -60.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 115.23% | -6.84% | -40.07% | -88.65% | -92.89% |
| Change in Net Operating Assets | -314.89% | -179.95% | -174.90% | -196.53% | 89.85% |
| Cash from Operations | -95.39% | -13.02% | -45.87% | 43.67% | 76.21% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -202.93% | -202.93% | -- | -- | -- |
| Cash Acquisitions | 100.00% | 100.00% | 65.95% | 65.98% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | 107.05% | 107.07% | -- |
| Total Debt Issued | -51.95% | -57.99% | -66.09% | -83.02% | -14.62% |
| Total Debt Repaid | -22.10% | -76.22% | -231.31% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -54.61% | -60.72% | -69.16% | -85.50% | -17.85% |
| Foreign Exchange rate Adjustments | -111.36% | -122.73% | -134.09% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -204.23% | -178.58% | -201.19% | -179.99% | 1,237.74% |